A single centre study of transitioning pulmonary arterial hypertension patients from parenteral prostacyclin therapy to oral selexipag
Latest Information Update: 04 Jul 2020
At a glance
- Drugs Selexipag (Primary) ; Epoprostenol
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- 20 May 2020 Results assessing transitioning patients from parenteral prostacyclins to oral selexipag regarding survival, functional status, and hemodynamics, presented at the 116th International Conference of the American Thoracic Society.
- 20 Sep 2019 New trial record